Taken together, our findings indicate that the enrichment of mesenchymal cancer cells and the change in the IC ligand repertoire towards CD80/CD155 expression act as predictive biomarkers of anti-PD-1/PD-L1 response in cSCC, HNSCC, and melanoma patient samples. This evidence concerns the gene PVR and melanoma.